Navigation Links
TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
Date:6/5/2008

ORLANDO, Fla., June 5 /PRNewswire/ -- New research presented at the recent American Urological Association Conference by Urologist Joel L. Marmar, M.D., showed that among men who previously failed to achieve erections on Viagra, Levitra and Cialis type tablets, 40% achieved an erection sufficient for penetration during sexual intercourse after given a single dose of a novel treatment called TriMix gel.

The research involved forty two (42) men diagnosed with erectile dysfunction and various other conditions such as high blood pressure, high cholesterol, diabetes and removal of the prostate. The average age was 55. All trial participants had previously failed on Viagra, Levitra or Cialis type tablets.

Test results were documented using various methodologies such as penile buckling pressures, RigiScans (an instrument that documents penile rigidity) and Erection Hardness Scores (EHS). All test participants experienced some degree of tumescence or increased blood flow and 17 of the patients or 40%, experienced erections sufficient for penetration during sexual intercourse.

Typically, trimix compound in liquid form requires refrigeration and the patient must use a needle to self inject. TriMix gel does not require refrigeration and does not use a needle. It allows the patient to carry the medicine on his person at room temperature. More importantly, an ED patient would not have to use a needle to self inject before sexual intercourse.

Dr. Marmar stated, "Among a group of men who previously failed to achieve erections on Viagra, Levitra and Cialis type tablets, TriMix-gel demonstrated statistically significant greater Erection Hardness Scores. TriMix gel may offer ED patients an elegant alternative to penile injection."
For more information visit http://www.trimixgel.com

Contact

T.J. Harkins

TriMix Laboratories

Cherry Hill, NJ

856-428-7008 x11

TJ (at) TriMixgel (dot) com


'/>"/>
SOURCE TriMix Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
2. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
3. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
4. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
11. CureDMs Diabetes Therapy Achieves Major Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term ... Since first offering the procedure in April of 2015, Florida Hospital Pepin Heart ...
(Date:5/5/2016)... Kansas (PRWEB) , ... May 05, 2016 , ... ... that some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian ... of red, green, and brown seaweeds. The pair observed that when photosynthetically active ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of Western ... host the 2016 National SACA Leadership Conference on the Portland campus September 23-25. ... officers to come together and develop skills to be future leaders in the ...
Breaking Medicine News(10 mins):